Semi-automated trajectory planning reduced workflow time and needle use while maintaining clinically acceptable target coverage and organ-at-risk doses.
Risk-adapted esophagus-sparing radiotherapy maintained target coverage, with grade 3 esophagitis in only 1.25% of high-risk patients.
Bone marrow-sparing planning reduced pelvic marrow dose, but heterogeneous evidence did not confirm a consistent reduction in hematologic toxicity.
A reusable positioning pouch displaced the genitalia from the treatment field while receiving high satisfaction ratings from patients and radiation therapists.
Four-dimensional prompt-gamma imaging detected clinically relevant proton range shifts associated with anatomical change during pancreatic proton therapy.
A single 19-Gy fraction achieved 92.9% three-year biochemical relapse-free survival with limited grade 2 gastrointestinal and genitourinary toxicity.
Radioresistant tumors showed impaired ferroptosis and regulatory T-cell accumulation, while sorafenib enhanced the response to irradiation in mice.
Concurrent chemotherapy improved progression-free survival without a significant overall survival benefit in early primary tumors with low-volume nodal disease.
Preoperative single-fraction and fractionated stereotactic radiotherapy produced similarly low composite event rates after resection of brain metastases.
FLASH radiotherapy preserved hepatic structure and metabolic homeostasis while maintaining tumor control in a preclinical breast cancer model.
Standardized two-hour fasting produced reproducible stomach volumes in only 42% of patients receiving magnetic resonance-guided pancreatic stereotactic radiotherapy.
Patients reported persistently worse quality of life and functioning approximately two years after chemoradiotherapy than matched individuals without cancer.
Circulating lymphocyte counts remained stable during brain radiotherapy without concurrent chemotherapy, consistent with low estimated blood and cervical lymph-node dose
A macro Monte Carlo framework reproduced reference dose calculations for very high energy electron beams up to 250 megaelectronvolts while improving computational efficiency by as much as twenty-sevenfold.
A hybrid foundation-model framework achieved 94% lesion-wise sensitivity and was preferred over physician-generated brain metastasis contours in blinded, bias-adjusted comparisons.